Retatrutide is an investigational medication being studied as a next-generation approach to obesity and metabolic disease. It simultaneously targets GLP-1, GIP, and glucagon receptors, giving it a different mechanism from medications that act on only one or two of those pathways.

​

Clinical trials have reported substantial reductions in body weight along with improvements in several metabolic measures. Researchers are also studying Retatrutide in connection with blood sugar regulation, cardiovascular risk factors, liver fat, mobility, and obesity-related conditions.

​

The amount of attention surrounding Retatrutide comes from the magnitude of weight loss seen in clinical research. However, it remains important to understand that an investigational therapy is different from an established, routinely approved medication, and its safety, dosing, indications, and long-term role continue to be studied.

​

At Shelson Integrative Health, weight management is treated as much more than changing a number on the scale. Dr. Matthew J. Shelson considers body composition, metabolic markers, nutrition, activity, medications, mobility, health history, and long-term sustainability.

​

Meaningful weight reduction can potentially make movement easier, improve metabolic health, increase activity tolerance, and reduce some of the physical burden associated with excess body weight. The objective is to build better health along the way - not simply chase rapid weight loss.